Results 11 to 20 of about 20,678 (258)
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study [PDF]
Endocrinology and Metabolism, 2016 BackgroundThe use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been ...
Jaehyun Bae +8 more
doaj +1 more source
PLoS ONE, 2020 Background and objectiveDipeptidyl peptidase-4 (DPP-4) inhibitors have been suggested to have pancreatic beta-cell preserving effect according to studies using homeostatic model of assessment for beta-cell function (HOMA-β).
Masahiro Takahashi +3 more
doaj +1 more source
PLoS ONE, 2020 BACKGROUND:Cisplatin is a highly effective chemotherapeutic agent. However, acute kidney injury (AKI) limits its subsequent use, resulting in poor cancer prognosis.
Takamasa Iwakura +5 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2017 Background Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established.
Hiroshi Nomoto +7 more
doaj +1 more source
International Journal of Endocrinology, 2014 Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use.
Hasniza Zaman Huri +2 more
doaj +1 more source
DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy? [PDF]
Diabetes, 2014 There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade.
Usha, Panchapakesan, Carol A, Pollock
openaire +2 more sources
BMC Endocrine Disorders, 2019 Background Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA1C and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia.
Fu-Shun Yen +6 more
doaj +1 more source
Cardiovascular effects of the DPP-4 inhibitors
Diabetes and Vascular Disease Research, 2012 Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP.
Tessey, Jose, Silvio E, Inzucchi
openaire +2 more sources
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine +8 more
doaj +1 more source
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2015 BackgroundPredictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus.
Shusuke Yagi +15 more
doaj +1 more source